List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7955077/publications.pdf Version: 2024-02-01



ΜΑΡΙΟ Ο.Δ.

#	Article	IF	CITATIONS
1	Chronic Kidney Disease and CoronaryÂArtery Disease. Journal of the American College of Cardiology, 2019, 74, 1823-1838.	1.2	403
2	Enhanced Expression of Lp-PLA ₂ and Lysophosphatidylcholine in Symptomatic Carotid Atherosclerotic Plaques. Stroke, 2008, 39, 1448-1455.	1.0	156
3	Osteocalcin Expression by Circulating Endothelial Progenitor Cells in Patients With Coronary Atherosclerosis. Journal of the American College of Cardiology, 2008, 52, 1314-1325.	1.2	155
4	Relationship Between Cardiovascular Risk as Predicted by Established Risk Scores Versus Plaque Progression as Measured by Serial Intravascular Ultrasound in Left Main Coronary Arteries. Circulation, 2004, 110, 1579-1585.	1.6	140
5	Functional anatomy and hemodynamic characteristics of vasa vasorum in the walls of porcine coronary arteries. , 2003, 272A, 526-537.		122
6	Dysregulation of the Ubiquitin-Proteasome System in Human Carotid Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 2132-2139.	1.1	110
7	Complete Versus Incomplete Revascularization With Coronary Artery Bypass Graft or Percutaneous Intervention in Stable Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2012, 5, 597-604.	1.4	91
8	Rethinking Primary Prevention of Atherosclerosis-Related Diseases. Circulation, 2006, 114, 2517-2527.	1.6	88
9	Inflammatory and injury signals released from the post-stenotic human kidney. European Heart Journal, 2013, 34, 540-548.	1.0	88
10	Contemporary Arterial Access in the Cardiac Catheterization Laboratory. JACC: Cardiovascular Interventions, 2017, 10, 2233-2241.	1.1	82
11	Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 96, 836-849.	2.6	80
12	Segmental Heterogeneity of Vasa Vasorum Neovascularization in Human Coronary Atherosclerosis. JACC: Cardiovascular Imaging, 2010, 3, 32-40.	2.3	76
13	Osteocalcin positive CD133+/CD34-/KDR+ progenitor cells as an independent marker for unstable atherosclerosis. European Heart Journal, 2012, 33, 2963-2969.	1.0	71
14	Novel Transcatheter Mitral Valve Prosthesis for Patients With Severe Mitral Annular Calcification. Journal of the American College of Cardiology, 2019, 74, 1431-1440.	1.2	70
15	Coronary endothelial dysfunction in humans is associated with coronary retention of osteogenic endothelial progenitor cells. European Heart Journal, 2010, 31, 2909-2914.	1.0	69
16	Role of Circulating Osteogenic Progenitor Cells in Calcific Aortic Stenosis. Journal of the American College of Cardiology, 2012, 60, 1945-1953.	1.2	64
17	Remote ischemic preconditioning immediately before percutaneous coronary intervention does not impact myocardial necrosis, inflammatory response, and circulating endothelial progenitor cell counts: A single center randomized sham controlled trial. Catheterization and Cardiovascular Interventions 2013 81 930-936	0.7	64
18	Increased spatial vasa vasorum density in the proximal LAD in hypercholesterolemia—Implications for vulnerable plaque-development. Atherosclerosis, 2007, 192, 246-252.	0.4	61

#	Article	IF	CITATIONS
19	Prevention of vasa vasorum neovascularization attenuates early neointima formation in experimental hypercholesterolemia. Basic Research in Cardiology, 2009, 104, 695-706.	2.5	61
20	Polyphenol-rich cranberry juice has a neutral effect on endothelial function but decreases the fraction of osteocalcin-expressing endothelial progenitor cells. European Journal of Nutrition, 2013, 52, 289-296.	1.8	61
21	Clinical Characteristics and OutcomesÂofÂSTEMI Patients With Cardiogenic Shock and Cardiac Arrest. JACC: Cardiovascular Interventions, 2020, 13, 1211-1219.	1.1	56
22	Expression of lipoprotein-associated phospholipase A2 in carotid artery plaques predicts long-term cardiac outcome. European Heart Journal, 2009, 30, 2930-2938.	1.0	50
23	Possible Association Between COVID-19ÂVaccine and Myocarditis. JACC: Cardiovascular Imaging, 2021, 14, 1856-1861.	2.3	49
24	Differential distribution of vasa vasorum in different vascular beds in humans. Atherosclerosis, 2008, 199, 47-54.	0.4	47
25	Metaâ€analysis of the impact of successful chronic total occlusion percutaneous coronary intervention on left ventricular systolic function and reverse remodeling. Journal of Interventional Cardiology, 2018, 31, 562-571.	0.5	47
26	Effect of the C825T polymorphism of the G protein β3 subunit on the systolic blood pressure–lowering effect of clonidine in young, healthy male subjects. Clinical Pharmacology and Therapeutics, 2003, 74, 53-60.	2.3	44
27	Incidence, predictors, management and outcomes of coronary perforations. Catheterization and Cardiovascular Interventions, 2019, 93, 48-56.	0.7	41
28	Ischemic Stroke With Cerebral Protection System During Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2020, 13, 2149-2155.	1.1	39
29	Role of vasa vasorum in transendothelial solute transport in the coronary vessel wall: a study with cryostatic micro-CT. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 287, H2346-H2351.	1.5	35
30	Patients with an HbA1c in the Prediabetic and Diabetic Range Have Higher Numbers of Circulating Cells with Osteogenic and Endothelial Progenitor Cell Markers. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4761-4768.	1.8	34
31	Spectrum of remodeling behavior observed with serial Long-Term (≥12 months) Follow-Up intravascular ultrasound studies in left main coronary arteries. American Journal of Cardiology, 2004, 93, 1107-1113.	0.7	33
32	Laser Doppler imager (LDI) scanner and intradermal injection for in vivo pharmacology in human skin microcirculation: responses to acetylcholine, endothelin-1 and their repeatability. British Journal of Clinical Pharmacology, 2005, 59, 511-519.	1.1	33
33	Effects of Bisphosphonate Treatment on Circulating Osteogenic Endothelial Progenitor Cells in Postmenopausal Women. Mayo Clinic Proceedings, 2013, 88, 46-55.	1.4	31
34	Coronary microvascular endothelial dysfunction is an independent predictor of development of osteoporosis in postmenopausal women. Vascular Health and Risk Management, 2014, 10, 533.	1.0	31
35	Causes and Clinical Outcomes of Patients Who Are Ineligible for Transcatheter Mitral Valve Replacement. JACC: Cardiovascular Interventions, 2019, 12, 196-204.	1.1	30
36	Relationship between arterial diameter and perfused tissue volume in myocardial microcirculation: a micro-CT-based analysis. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 286, H2386-H2392.	1.5	29

#	Article	IF	CITATIONS
37	Prospective Evaluation for Hypoattenuated Leaflet Thickening Following Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2019, 123, 658-666.	0.7	29
38	The nitric oxide synthase inhibitor L-NMMA potentiates noradrenaline-induced vasoconstriction: effects of the alpha2-receptor antagonist yohimbine. Journal of Hypertension, 2001, 19, 907-911.	0.3	28
39	Remodeling Index Compared to Actual Vascular Remodeling in Atherosclerotic Left Main Coronary Arteries as Assessed With Long-Term (≥12 Months) Serial Intravascular Ultrasound. Journal of the American College of Cardiology, 2006, 47, 1363-1368.	1.2	28
40	Osteogenic monocytes within the coronary circulation and their association with plaque vulnerability in patients with early atherosclerosis. International Journal of Cardiology, 2015, 181, 57-64.	0.8	28
41	Contemporary Reasons and Clinical Outcomes for Patients With Severe, Symptomatic Aortic Stenosis Not Undergoing Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2018, 11, e007220.	1.4	26
42	Use of routinely captured echocardiographic data in the diagnosis of severe aortic stenosis. Heart, 2019, 105, 112-116.	1.2	26
43	Vasa vasorum growth in the coronary arteries of newborn pigs. Anatomy and Embryology, 2004, 208, 351-7.	1.5	25
44	Volumetric assessment of ulcerated ruptured coronary plaques with three-dimensional intravascular ultrasound in vivo. American Journal of Cardiology, 2003, 91, 992-996.	0.7	24
45	Prospective Evaluation of the Eyeball Test for Assessing Frailty in Patients With Valvular Heart Disease. Journal of the American College of Cardiology, 2016, 68, 2911-2912.	1.2	22
46	Severe Mitral Annular Calcification. JACC: Cardiovascular Interventions, 2017, 10, 1178-1179.	1.1	21
47	Accelerated Coronary Plaque Progression and Endothelial Dysfunction. JACC: Cardiovascular Imaging, 2014, 7, 103-104.	2.3	20
48	Left Ventricular Remodeling After Transcatheter Mitral Valve Replacement With Tendyne. JACC: Cardiovascular Interventions, 2020, 13, 2038-2048.	1.1	20
49	Hypertension and Hypercholesterolemia Differentially Affect the Function and Structure of Pig Carotid Artery. Hypertension, 2007, 50, 1063-1068.	1.3	19
50	Percutaneous Treatment of Aortic and Mitral Valve Paravalvular Regurgitation. Current Cardiology Reports, 2013, 15, 388.	1.3	19
51	Temporal changes in patient characteristics and outcomes in STâ€segment elevation myocardial infarction 2003–2018. Catheterization and Cardiovascular Interventions, 2021, 97, 1109-1117.	0.7	18
52	Vulnerable Plaque: Detection and Management. Medical Clinics of North America, 2007, 91, 573-601.	1.1	17
53	Natural history observations in moderate aortic stenosis. BMC Cardiovascular Disorders, 2021, 21, 108.	0.7	17
54	Relation of Nonperfused Myocardial Volume and Surface Area to Left Ventricular Performance in Coronary Microembolization, Circulation, 2004, 110, 1946-1952.	1.6	15

#	Article	IF	CITATIONS
55	MitraClip patient selection: inclusion and exclusion criteria for optimal outcomes. Annals of Cardiothoracic Surgery, 2018, 7, 771-775.	0.6	14
56	Endothelin-B-receptor-selective antagonist inhibits endothelin-1 induced potentiation on the vasoconstriction to noradrenaline and angiotensin II. Journal of Hypertension, 2004, 22, 1909-1916.	0.3	12
57	Cardiac shunt calculations made easy: A caseâ€based approach. Catheterization and Cardiovascular Interventions, 2010, 76, 137-142.	0.7	12
58	Transcatheter Mitral Valve Replacement with Tendyne. Interventional Cardiology Clinics, 2019, 8, 295-300.	0.2	12
59	Complementary Transcatheter Therapy for Mitral Regurgitation. Journal of the American College of Cardiology, 2019, 73, 1103-1104.	1.2	12
60	<scp>Pointâ€ofâ€care</scp> ultrasound: Closing guideline gaps in screening for valvular heart disease. Clinical Cardiology, 2020, 43, 1368-1375.	0.7	12
61	Impaired myocardial perfusion reserve in experimental hypercholesterolemia is independent of myocardial neovascularization. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H2449-H2458.	1.5	11
62	Association of Guideline Adherence for Serial Evaluations With Survival and Adverse Clinical Events in Patients With Asymptomatic Severe Aortic Stenosis. JAMA Cardiology, 2017, 2, 1141.	3.0	10
63	Computed Tomographic Angiography-Derived Risk Factors for Vascular Complications in Percutaneous Transfemoral Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2019, 124, 98-104.	0.7	10
64	The Need for Transcatheter Mitral ValveÂReplacement. Journal of the American College of Cardiology, 2019, 73, 1247-1249.	1.2	10
65	Changes in quality of life in patients with lowâ€flow aortic stenosis undergoing transcatheter aortic valve replacement. Catheterization and Cardiovascular Interventions, 2020, 96, 972-978.	0.7	10
66	Prosthesis-patient mismatch defined by cardiac computed tomography versus echocardiography after transcatheter aortic valve replacement. Journal of Cardiovascular Computed Tomography, 2021, 15, 403-411.	0.7	10
67	Assessment of Individual Operator Performance Using a Risk-Adjustment Model for Percutaneous Coronary Interventions. Mayo Clinic Proceedings, 2013, 88, 1250-1258.	1.4	9
68	Prevalence, Trends, and Outcomes of Higher-Risk Percutaneous Coronary Interventions Among Patients Without Acute Coronary Syndromes. Cardiovascular Revascularization Medicine, 2019, 20, 289-292.	0.3	9
69	Transcatheter repair of tricuspid regurgitation with MitraClip. Progress in Cardiovascular Diseases, 2019, 62, 488-492.	1.6	9
70	Imatinib ameliorates fibrosis in uraemic cardiac disease in BALB/c without improving cardiac function. Nephrology Dialysis Transplantation, 2010, 25, 1817-1824.	0.4	8
71	Association of baseline and change in global longitudinal strain by computed tomography with post-transcatheter aortic valve replacement outcomes. European Heart Journal Cardiovascular Imaging, 2022, 23, 476-484.	0.5	8
72	Renin inhibition with aliskiren lowers circulating endothelial progenitor cells in patients with early atherosclerosis. Journal of Hypertension, 2013, 31, 632-635.	0.3	7

#	Article	IF	CITATIONS
73	Maneuvers for technical success with transcatheter mitral valve repair. Catheterization and Cardiovascular Interventions, 2018, 92, 617-626.	0.7	7
74	Transcatheter Closure of Complex Ascending Aortic Pseudoaneurysms After Cardiac Surgery. Circulation: Cardiovascular Interventions, 2018, 11, e007052.	1.4	7
75	Review – 3D Micro CT Imaging of Renal Micro-Structural Changes. Nephron Clinical Practice, 2006, 103, c66-c70.	2.3	6
76	Current Status of Catheter-Based Treatment of Mitral Valve Regurgitation. Current Cardiology Reports, 2017, 19, 38.	1.3	6
77	Expecting the unexpected: preventing and managing the consequences of coronary perforations. Expert Review of Cardiovascular Therapy, 2018, 16, 805-814.	0.6	6
78	Neo-Left Ventricular Outflow Tract Modification With Alcohol Septal Ablation Before Tendyne Transcatheter Mitral Valve Replacement. JACC: Cardiovascular Interventions, 2020, 13, 2078-2080.	1.1	6
79	Right ventricular dysfunction by computed tomography associates with outcomes in severe aortic stenosis patients undergoing transcatheter aortic valve replacement. Journal of Cardiovascular Computed Tomography, 2022, 16, 158-165.	0.7	6
80	Challenges and outcomes of the double kissing crush stenting technique: Insights from the PROGRESSâ€BIFURCATION registry. Catheterization and Cardiovascular Interventions, 2022, 99, 1038-1044.	0.7	6
81	Frontiers in Nephrology. Journal of the American Society of Nephrology: JASN, 2007, 18, 2836-2842.	3.0	5
82	Relationship between surface area of nonperfused myocardium and extravascular extraction of contrast agent following coronary microembolization. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2011, 301, R430-R437.	0.9	5
83	Failing left ventricle to ascending aorta conduit—Hybrid implantation of a melody valve and NuMed covered stent. Catheterization and Cardiovascular Interventions, 2014, 83, 778-781.	0.7	5
84	Left Main Coronary Artery Protection During Transcatheter Aortic Valve Deployment. Journal of the American College of Cardiology, 2014, 63, 1583.	1.2	5
85	Impact of Transcatheter Mitral Valve Repair on Left Ventricular Remodeling in Secondary Mitral Regurgitation: A Meta-Analysis. Structural Heart, 2018, 2, 541-547.	0.2	5
86	Clinical Outcomes of Mitral Valve Disease With Mitral Annular Calcification. American Journal of Cardiology, 2022, 174, 107-113.	0.7	5
87	Necrotizing Skin Ulceration in Antibiotic-Induced Agranulocytosis. Mayo Clinic Proceedings, 2006, 81, 1527.	1.4	4
88	An Update on Transcatheter Aortic Valve Replacement. Current Problems in Cardiology, 2013, 38, 245-283.	1.1	4
89	Pulmonary Hypertension in Patients Undergoing Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2015, 8, e002253.	1.4	4
90	Impact of sleep deprivation on the outcomes of percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2018, 92, 1118-1125.	0.7	4

#	Article	IF	CITATIONS
91	Coronary revascularization and use of hemodynamic support in acute coronary syndromes. Hellenic Journal of Cardiology, 2019, 60, 165-170.	0.4	4
92	Clinical and Economic Outcomes of the Minimalist Approach for Transcatheter Aortic Valve Replacement. Structural Heart, 2019, 3, 138-143.	0.2	4
93	Identification of Subclinical Myocardial Dysfunction and Association with Survival after Transcatheter Mitral Valve Repair. Journal of the American Society of Echocardiography, 2020, 33, 1474-1480.	1.2	4
94	Transcatheter aortic valve replacement in patients with severe comorbidities: A retrospective cohort study. Catheterization and Cardiovascular Interventions, 2021, 97, E253-E262.	0.7	4
95	Finding the Culprit. JACC: Cardiovascular Interventions, 2019, 12, 2106-2109.	1.1	3
96	Outcomes after pacemaker implantation in patients with new-onset left bundle-branch block after transcatheter aortic valve replacement. American Heart Journal, 2019, 218, 128-132.	1.2	3
97	Transcatheter closure of an aorto–right ventricular fistula after TAVR. Cardiovascular Intervention and Therapeutics, 2019, 34, 290-292.	1.2	3
98	Impact of the Commercial Introduction of Transcatheter Mitral Valve Repair on Mitral Surgical Practice. Journal of the American Heart Association, 2020, 9, e014874.	1.6	3
99	Adoptability and accuracy of <scp>pointâ€ofâ€care</scp> ultrasound in screening for valvular heart disease in the primary care setting. Journal of Clinical Ultrasound, 2022, 50, 265-270.	0.4	3
100	Transcatheter Mitral Valve Repair of Recurrent Mitral Regurgitation Following Mitral Surgery. JACC: Cardiovascular Interventions, 2019, 12, 1395-1397.	1.1	2
101	Challenges of Left Atrial Appendage Occlusion Using a Watchman After Transcatheter Mitral Valve Implantation With a Tendyne. JACC: Cardiovascular Interventions, 2020, 13, 1720-1722.	1.1	2
102	Invasive versus non-invasive assessment of valvuloarterial impedance in severe aortic stenosis. Open Heart, 2020, 7, e001240.	0.9	2
103	Don't neglect the octogenarians—DES for everyone!?. Nature Reviews Cardiology, 2012, 9, 189-190.	6.1	1
104	Quantifying the Costs of Transcatheter Aortic Valve Replacement Hesitancy. Journal of the American Heart Association, 2018, 7, e010610.	1.6	1
105	Waiting to Exhale. Circulation: Cardiovascular Interventions, 2018, 11, e006749.	1.4	1
106	Cardiac Amyloidosis is Underdiagnosed in Patients Undergoing Transcatheter Aortic Valve Replacement. Structural Heart, 2020, 4, 512-514.	0.2	1
107	Anticoagulation in Patients with Aortic Stenosis and Atrial Fibrillation. Structural Heart, 2020, 4, 360-368.	0.2	1
108	Relation of Guideline Adherence to Outcomes in Patients With Asymptomatic Severe Primary Mitral Regurgitation. American Journal of Cardiology, 2021, 155, 113-120.	0.7	1

MARIO GöSSL

#	Article	IF	CITATIONS
109	Percutaneous Treatment of Mitral Regurgitation: Present and Future. Journal of the Minneapolis Heart Institute Foundation, 2017, 1, 113-123.	0.0	1
110	"Commissural drop―wiring technique facilitates catheter crossing of severely stenotic aortic valve. Chinese Medical Journal, 2021, 134, 245-246.	0.9	1
111	Transcatheter closure of periprosthetic leaks. Progress in Cardiovascular Diseases, 2022, 72, 96-101.	1.6	1
112	Cardiac shunt calculations made easy-A case based approach. Catheterization and Cardiovascular Interventions, 2011, 77, 461-461.	0.7	0
113	Where Are the Boundaries for Transcatheter Valve Therapy?. JACC: Cardiovascular Interventions, 2016, 9, 1372-1373.	1.1	0
114	Transcatheter Aortic Valve ReplacementÂVersus Surgical AorticÂValve Replacement. JACC: Cardiovascular Interventions, 2018, 11, 2217-2219.	1.1	0
115	Simultaneous deployment of multiple device occluders and the anchor wire technique for a treatment of paravalvular defect of a surgical mitral ring. Cardiovascular Intervention and Therapeutics, 2019, 34, 191-193.	1.2	0
116	MY APPROACH to patients with asymptomatic aortic stenosis (with normal left ventricular ejection) Tj ETQq0 0 C) rgBT /Ov	erlock 10 Tf 5

117	Valvular Heart Diseases Surveillance: A Commanding Necessity. Mayo Clinic Proceedings, 2020, 95, 2585-2588.	1.4	0
118	Periprocedural Antithrombotic Therapy: A Practical Guide for Clinical Practice. Journal of the Minneapolis Heart Institute Foundation, 2017, 1, 24-29.	0.0	0
119	Transcatheter mitral valve replacement. , 2020, , 463-481.		0
120	Computed Tomography Planning for Transcatheter Mitral Valve Replacement. Structural Heart, 2022, 6, 100012.	0.2	0